Search for content, post, videos

Heartseed and Novo Nordisk announce first patient dosed in clinical study

Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has give
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.